NRBO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.54%

Insider Buying (Last 12 Months): $7,964,378.90

Insider Selling (Last 12 Months): $1,526.25

NeuroBo Pharmaceuticals Insider Trading History Chart

NeuroBo Pharmaceuticals Share Price & Price History

^$3.19

▼ -0.07 (-2.15%)

As of 09/20/2024 01:00 AM ET

Days: 30 | 90 | 365

Forget Trump and Kamala

From Investors Alley | Ad

I hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.

THIS CALENDAR is the only thing that matters for you and your financial health right now.

NeuroBo Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/12/2024	St Co. Ltd Dong-A	Major Shareholder	Sell	407	$3.75	$1,526.25	5,347,792
6/23/2024	St Co. Ltd Dong-A	Major Shareholder	Buy	2,544,530	$3.13	$7,964,378.90	5,348,229

Forget Trump and Kamala

From Investors Alley | Ad

I hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.

THIS CALENDAR is the only thing that matters for you and your financial health right now.

SEC Filings (Institutional Ownership Changes) for NeuroBo Pharmaceuticals (NASDAQ:NRBO)

1.37% of NeuroBo Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

NeuroBo Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	696,829	$3.37M	0.0%	N/A	14.204%
8/15/2024	Affinity Asset Advisors LLC	89,222	$0.43M	0.0%	N/A	1.819%
2/14/2022	Murchinson Ltd.	205,256	$0.25M	0.0%	N/A	0.772%
11/9/2021	BlackRock Inc.	44,579	$0.17M	0.0%	-11.3%	0.200%
9/3/2021	Parametric Portfolio Associates LLC	16,530	$55K	0.0%	N/A	0.074%
8/16/2021	State Street Corp	15,878	$53K	0.0%	-78.6%	0.071%
8/13/2021	Northern Trust Corp	24,579	$82K	0.0%	-68.9%	0.110%
8/13/2021	Vanguard Group Inc.	477,918	$1.59M	0.0%	-30.2%	2.145%
8/12/2021	Advisory Services Network LLC	8,550	$28K	0.0%	N/A	0.038%
8/12/2021	Ergoteles LLC	30,800	$0.10M	0.0%	N/A	0.138%
8/11/2021	Deutsche Bank AG	31,090	$0.10M	0.0%	+1,016.3%	0.140%
8/4/2021	Mount Yale Investment Advisors LLC	57,425	$0.19M	0.0%	N/A	0.258%
5/18/2021	California State Teachers Retirement System	9,817	$43K	0.0%	+52.1%	0.044%
5/17/2021	Goldman Sachs Group Inc.	10,056	$44K	0.0%	N/A	0.045%
5/13/2021	Bank of New York Mellon Corp	19,178	$84K	0.0%	N/A	0.087%
5/12/2021	JPMorgan Chase & Co.	18,449	$81K	0.0%	+69.4%	0.083%
5/7/2021	BlackRock Inc.	226,013	$1M	0.0%	+2.7%	1.019%
2/19/2021	JPMorgan Chase & Co.	10,889	$57K	0.0%	+234.8%	0.055%
2/11/2021	Northern Trust Corp	80,860	$0.43M	0.0%	-5.4%	0.411%
2/9/2021	Wells Fargo & Company MN	17,562	$92K	0.0%	+1,213.5%	0.089%
2/5/2021	BlackRock Inc.	219,989	$1.15M	0.0%	+5.0%	1.339%
11/10/2020	State Street Corp	41,439	$0.23M	0.0%	+7.3%	0.252%
8/14/2020	Bank of America Corp DE	7,122	$57K	0.0%	-35.8%	0.043%

Data available starting January 2016

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.19

$3.08

$3.35

50 Day Range

MA: $3.83

$3.19

$5.00

52 Week Range

Now: $3.19

$2.90

$6.75

Volume

75,308 shs

Average Volume

491,105 shs

Market Capitalization

$15.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of NeuroBo Pharmaceuticals?: NeuroBo Pharmaceuticals' top insider investors include:
St Co Ltd Dong-A (Major Shareholder)
Learn More about top insider investors at NeuroBo Pharmaceuticals.
Who are the major institutional investors of NeuroBo Pharmaceuticals?: NeuroBo Pharmaceuticals' top institutional investors include:
Armistice Capital LLC — 14.20%
Affinity Asset Advisors LLC — 1.82%
Learn More about top institutional investors of NeuroBo Pharmaceuticals stock.
Which major investors are buying NeuroBo Pharmaceuticals stock?: During the previous quarter, NRBO stock was purchased by institutional investors including:
Armistice Capital LLC
Affinity Asset Advisors LLC